Adamas Wins Approval of Drug for Dyskinesia in Parkinson’s Patients

Drug Industry Daily
A A
The FDA approved Adamas Pharmaceuticals’ Gocovri (amantadine) for the treatment of dyskinesia in Parkinson’s disease patients receiving levodopa therapy, making it the first drug to be approved for that condition.

To View This Article:

Login

Subscribe To Drug Industry Daily